Waylis Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Waylis Therapeutics (US): 11 reconciled FDA prescription therapies (14.2% 2025 to 2030 cliff risk), $62.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies11
2025 to 2030 Patent-Cliff Revenue Exposure14.2%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$62.7M
2024 Medicare Part D Spend$61.9M
2024 Medicaid Spend$880K
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel